Citations (191)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (26)
Hamdi Nsairat, Abed Alqader Ibrahim, Areej M. Jaber, Sharif Abdelghany, Randa Atwan, Naeem Shalan, Hiba Abdelnabi, Fadwa Odeh, Mohamed El-Tanani & Walhan Alshaer. (2023) Liposome bilayer stability: emphasis on cholesterol and its alternatives. Journal of Liposome Research 0:0, pages 1-25.
Read now
Read now
Briana L. Scott, Chi D. Hornik & Kanecia Zimmerman. (2020) Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population. Expert Opinion on Drug Metabolism & Toxicology 16:7, pages 605-616.
Read now
Read now
Erik Őrfi, Tamás Mészáros, Mark Hennies, Tamás Fülöp, László Dézsi, Alexander Nardocci, László Rosivall, Péter Hamar, Barry W Neun, Marina A Dobrovolskaia, János Szebeni & Gábor Szénási. (2019) Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice. International Journal of Nanomedicine 14, pages 1563-1573.
Read now
Read now
Masoud Ghorbani & Ramin Farhoudi. (2018) Leishmaniasis in humans: drug or vaccine therapy?. Drug Design, Development and Therapy 12, pages 25-40.
Read now
Read now
Gerard M. Jensen. (2017) The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome®). Journal of Liposome Research 27:3, pages 173-179.
Read now
Read now
Linda Soo Hoo. (2017) Fungal fatal attraction: a mechanistic review on targeting liposomal amphotericin B (AmBisome®) to the fungal membrane. Journal of Liposome Research 27:3, pages 180-185.
Read now
Read now
G. M. Jensen & K. J. Jalkanen. (2017) Introduction to the 25th anniversary AmBisome® Festschrift. Journal of Liposome Research 27:3, pages 171-172.
Read now
Read now
Koji Takemoto & Katsunori Kanazawa. (2017) AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy. Journal of Liposome Research 27:3, pages 186-194.
Read now
Read now
Qamar Zia, Aijaz Ahmed Khan, Zubair Swaleha & Mohammad Owais. (2015) Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. International Journal of Nanomedicine 10, pages 1769-1790.
Read now
Read now
Angela S Loo, Saif A Muhsin & Thomas J Walsh. (2013) Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B
. Expert Opinion on Drug Safety 12:6, pages 881-895.
Read now
Read now
June-Woo Kang, Enkhzaya Davaa, Ye-Tae Kim & Jeong-Sook Park. (2010) A new vaginal delivery system of amphotericin B: a dispersion of cationic liposomes in a thermosensitive gel. Journal of Drug Targeting 18:8, pages 637-644.
Read now
Read now
T. Chang, J. A. Olson, R. T. Proffitt & J. P. Adler-Moore. (2010) Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B. Medical Mycology 48:2, pages 430-435.
Read now
Read now
Gerard M. Jensen & Tarquinus H. Bunch. (2007) Conventional Liposome Performance and Evaluation: Lessons from the Development of Vescan. Journal of Liposome Research 17:3-4, pages 121-137.
Read now
Read now
Winter J Gibbs, Richard H Drew & John R Perfect. (2005) Liposomal amphotericin B: clinical experience and perspectives. Expert Review of Anti-infective Therapy 3:2, pages 167-181.
Read now
Read now
G. Demartini, C. Lequaglie, P.P. Brega massone, F. Scaglione & F. Fraschini. (2005) Penetration of Amphotericin B in Human Lung Tissue after Single Liposomal Amphotericin B (AmBisome) Infusion. Journal of Chemotherapy 17:1, pages 82-85.
Read now
Read now
John H Rex & Sevtap Arikan. (2002) New agents for the treatment of systemic fungal infections – current status. Expert Opinion on Emerging Drugs 7:1, pages 3-32.
Read now
Read now
Sevtap Arikan & John H Rex. (2000) New agents for treatment of systemic fungal infections. Emerging Drugs 5:2, pages 135-160.
Read now
Read now
Leila Zarif, John R. Graybill, David Perlin & Raphael J. Mannino. (2000) Cochleates: New Lipid-Based Drug Delivery System. Journal of Liposome Research 10:4, pages 523-538.
Read now
Read now
Theodore F. Taraschi & Joseph M. Beggs. (2000) Letters. Journal of Liposome Research 10:1, pages 96-98.
Read now
Read now
G. M. Jensen, C. R. Skenes, T. H. Bunch, C. A. Weissman, N. Amirghahari, A. Satorius, K. L. Moynihan & C. G. S. Eley. (1999) Determination of the Relative Toxicity of Amphotericin B Formulations: A Red Blood Cell Potassium Release Assay. Drug Delivery 6:2, pages 81-88.
Read now
Read now
Mandip Singh Sachdeva. (1998) Drug targeting systems for cancer chemotherapy. Expert Opinion on Investigational Drugs 7:11, pages 1849-1864.
Read now
Read now
John W. Hiemenz & Thomas J. Walsh. (1998) Lipid Formulations of Amphotericin. Journal of Liposome Research 8:4, pages 443-467.
Read now
Read now
P.J. Sperry, D.J. Cua, S.A. Wetzel & J.P. Adler-Moore. (1998) Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Medical Mycology 36:3, pages 135-141.
Read now
Read now
P. Legrand, M. Chéron, L. Leroy & J. Bolard. (1997) Release of Amphotericin B from Delivery Systems and its Action Against Fungal and Mammalian Cells. Journal of Drug Targeting 4:5, pages 311-319.
Read now
Read now
Yechezkel Barenholz & Rivka Cohen. (1995) Rational design of amphiphile-based drug carriers and sterically stabilized carriers. Journal of Liposome Research 5:4, pages 905-932.
Read now
Read now
Francis C. Szoka & Mary Tang. (1993) Amphotericin B Formulated in Liposomes and Lipid Based Systems: A Review. Journal of Liposome Research 3:3, pages 363-375.
Read now
Read now
Articles from other publishers (165)
E.T. Aguayo Frías, D. Maza Vega, M.N. Calienni, C. Lillo, D.S. Vazquez, S.d.V. Alonso & J. Montanari. (2023) Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes. OpenNano 14, pages 100186.
Crossref
Crossref
Sourour Idoudi, Roua Ismail, Ousama Rachid, Abdelbary Elhissi & Alaaldin M. Alkilany. (2023) The Golden Liposomes: Preparation and Biomedical Applications of Gold-Liposome Nanocomposites. Journal of Nanotheranostics 4:3, pages 201-227.
Crossref
Crossref
Sarah BartholdNicole KunschkeXabier MurgiaBrigitta LoretzCristiane de Souza Carvalho-WodarzClaus-Michael Lehr. (2023) Overview of Inhaled Nanopharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery 36:3, pages 144-151.
Crossref
Crossref
Joris R. Delanghe, Jonas Himpe, Jerina Boelens, Dominique Benoit, Bram Gadeyne, Marijn M. Speeckaert & Frederick Verbeke. (2023) C-reactive protein interacts with amphotericin B liposomes and its potential clinical consequences. Clinical Chemistry and Laboratory Medicine (CCLM) 61:6, pages 1065-1068.
Crossref
Crossref
Erik Pieter van Geest, Sina Katharina Götzfried, David M. Klein, Nadiya Salitra, Sorraya Popal, Yurii Husiev, Corjan J. Van der Griend, Xuequan Zhou, Maxime A. Siegler, Gregory F. Schneider & Sylvestre Bonnet. (2022)
A
Lock‐and‐Kill
Anticancer Photoactivated Chemotherapy Agent
†
. Photochemistry and Photobiology 99:2, pages 777-786.
Crossref
Crossref
Mokshada Kumar, Priyanka Kulkarni, Shufang Liu, Nagendra Chemuturi & Dhaval K. Shah. (2023) Nanoparticle biodistribution coefficients: A quantitative approach for understanding the tissue distribution of nanoparticles. Advanced Drug Delivery Reviews 194, pages 114708.
Crossref
Crossref
Katharine E Stott, Melanie Moyo, Ajisa Ahmadu, Cheusisime Kajanga, Ebbie Gondwe, Wezzie Chimang’anga, Madalitso Chasweka, Tshepo B Leeme, Mooketsi Molefi, Awilly Chofle, Gabriella Bidwell, John Changalucha, Jenny Unsworth, Ana Jimenez-Valverde, David S Lawrence, Henry C Mwandumba, David G Lalloo, Thomas S Harrison, Joseph N Jarvis, William Hope & Anne-Grete Märtson. (2023) Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. Journal of Antimicrobial Chemotherapy 78:1, pages 276-283.
Crossref
Crossref
Fauzia Jamal, Ishrat Altaf, Ghufran Ahmed, Sheikh Asad, Hira Ahmad, Qamar Zia, Asim Azhar, Saba Farheen, Taj Shafi, Shabana Karim, Swaleha Zubair & Mohammad Owais. (2023) Amphotericin B Nano-Assemblies Circumvent Intrinsic Toxicity and Ensure Superior Protection in Experimental Visceral Leishmaniasis with Feeble Toxic Manifestation. Vaccines 11:1, pages 100.
Crossref
Crossref
Frédéric Frézard, Marta M. G. Aguiar, Lucas A. M. Ferreira, Guilherme S. Ramos, Thais T. Santos, Gabriel S. M. Borges, Virgínia M. R. Vallejos & Helane L. O. De Morais. (2022) Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations. Pharmaceutics 15:1, pages 99.
Crossref
Crossref
R J Brüggemann, G M Jensen & C Lass-Flörl. (2022) Liposomal amphotericin B—the past. Journal of Antimicrobial Chemotherapy 77:Supplement_2, pages ii3-ii10.
Crossref
Crossref
A Pagliuca & M Akova. (2022) Foreword. Journal of Antimicrobial Chemotherapy 77:Supplement_2, pages ii1-ii2.
Crossref
Crossref
Richard Marx, Jaeweon Lee, Yuri Svirkin, Seongkyu Yoon, Nelson Landrau, Md Abul Kaisar, Bin Qin, Jin H. Park, Khondoker Alam, Darby Kozak, Yan Wang, Xiaoming Xu, Jiwen Zheng & Benjamin Rivnay. (2022) Physicochemical surrogates for in vitro toxicity assessment of liposomal amphotericin B. International Journal of Pharmaceutics 628, pages 122273.
Crossref
Crossref
Shobha Kumari, Vikash Kumar, Ritesh Kumar Tiwari, Vidyanand Ravidas, Krishna Pandey & Ashish Kumar. (2022) Amphotericin B: A drug of choice for Visceral Leishmaniasis. Acta Tropica 235, pages 106661.
Crossref
Crossref
Antoine Al‐Achi, Mali Ram Gupta & William Craig Stagner. 2022. Integrated Pharmaceutics. Integrated Pharmaceutics
18
45
.
Antoine Al‐Achi, Mali Ram Gupta & William Craig Stagner. 2022. Integrated Pharmaceutics. Integrated Pharmaceutics
369
425
.
Payal Kesharwani, Kajal Kumari, Ritika Gururani, Smita Jain & Swapnil Sharma. (2022) Approaches to Address PK-PD Challenges of Conventional Liposome Formulation
with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update
on Modified Liposomal Drug Delivery System. Current Drug Metabolism 23:9, pages 678-692.
Crossref
Crossref
Yuri Svirkin, Jaeweon Lee, Richard Marx, Seongkyu Yoon, Nelson Landrau, Md Abul Kaisar, Bin Qin, Jin H. Park, Khondoker Alam, Darby Kozak, Yan Wang, Xiaoming Xu, Jiwen Zheng & Benjamin Rivnay. (2022) Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity. Asian Journal of Pharmaceutical Sciences 17:4, pages 544-556.
Crossref
Crossref
Roman I. Koning, Hildo Vader, Martijn van Nugteren, Peter A. Grocutt, Wen Yang, Ludovic L. R. Renault, Abraham J. Koster, Arnold C. F. Kamp & Michael Schwertner. (2022) Automated vitrification of cryo-EM samples with controllable sample thickness using suction and real-time optical inspection. Nature Communications 13:1.
Crossref
Crossref
Adrián Vicente-Barrueco, Ángel Carlos Román, Trinidad Ruiz-Téllez & Francisco Centeno. (2022) In Silico Research of New Therapeutics Rotenoids Derivatives against Leishmania amazonensis Infection. Biology 11:1, pages 133.
Crossref
Crossref
Akash Chaurasiya, Amruta Gorajiya & Jayabalan Nirmal. 2022. Multifunctional Nanocarriers. Multifunctional Nanocarriers
475
500
.
Marc-Phillip Mast, Harshvardhan Modh, Carole Champanhac, Jiong-Wei Wang, Gerrit Storm, Johannes Krämer, Volker Mailänder, Giorgia Pastorin & Matthias G. Wacker. (2021) Nanomedicine at the crossroads – A quick guide for IVIVC. Advanced Drug Delivery Reviews 179, pages 113829.
Crossref
Crossref
Natália Kronbauer Oliveira, Luiza Abrahão Frank, Eamim Daidrê Squizani, Julia Catarina Vieira Reuwsaat, Bárbara Machado Marques, Heryk Motta, Ane Wichine Acosta Garcia, Uriel Perin Kinskovski, Vanessa Abreu Barcellos, Augusto Schrank, Adriana Raffin Pohlmann, Charley Christian Staats, Sílvia Stanisçuaski Guterres, Marilene Henning Vainstein & Lívia Kmetzsch. (2021) New nanotechnological formulation based on amiodarone-loaded lipid core nanocapsules displays anticryptococcal effect. European Journal of Pharmaceutical Sciences 162, pages 105816.
Crossref
Crossref
José Ramón Azanza Perea. (2021) Anfotericina B liposomal: farmacología clínica, farmacocinética y farmacodinamia. Revista Iberoamericana de Micología 38:2, pages 52-55.
Crossref
Crossref
Peter van Hoogevest, Harry Tiemessen, Josbert M. Metselaar, Simon Drescher & Alfred Fahr. (2021) The Use of Phospholipids to Make Pharmaceutical Form Line Extensions. European Journal of Lipid Science and Technology 123:4.
Crossref
Crossref
Alexander Yu Maksimov, Svetlana Yu Balandina, Pavel A. Topanov, Irina V. Mashevskaya & Sandeep Chaudhary. (2021) Organic Antifungal Drugs and Targets of Their Action. Current Topics in Medicinal Chemistry 21:8, pages 705-736.
Crossref
Crossref
Miriam E. Klein, Max Rieckmann, Daniel Sedding, Gerd Hause, Annette Meister, Karsten Mäder & Henrike Lucas. (2021) Towards the Development of Long Circulating Phosphatidylserine (PS)- and Phosphatidylglycerol (PG)-Enriched Anti-Inflammatory Liposomes: Is PEGylation Effective?. Pharmaceutics 13:2, pages 282.
Crossref
Crossref
Katarzyna Juszkiewicz, Aleksander F. Sikorski & Aleksander Czogalla. (2020) Building Blocks to Design Liposomal Delivery Systems. International Journal of Molecular Sciences 21:24, pages 9559.
Crossref
Crossref
Yayuan Liu, Zihan Mei, Ling Mei, Jie Tang, Wenmin Yuan, Santhanakrishnan Srinivasan, Rose Ackermann & Anna S. Schwendeman. (2020) Analytical method development and comparability study for AmBisome® and generic Amphotericin B liposomal products. European Journal of Pharmaceutics and Biopharmaceutics 157, pages 241-249.
Crossref
Crossref
Kengo Banshoya, Yoshiharu Kaneo, Tetsuro Tanaka, Shigechika Yamamoto & Hiroshi Maeda. (2020) Development of an amphotericin B micellar formulation using cholesterol-conjugated styrene-maleic acid copolymer for enhancement of blood circulation and antifungal selectivity. International Journal of Pharmaceutics 589, pages 119813.
Crossref
Crossref
Sonja Horvat, Yidong Yu, Szalbolcs Böjte, Ingrid Teßmer, Douglas W. Lowman, Zuchao Ma, David L. Williams, Andreas Beilhack, Krystyna Albrecht & Jürgen Groll. (2020)
Engineering Nanogels for Drug Delivery to Pathogenic Fungi
Aspergillus fumigatus
by Tuning Polymer Amphiphilicity
. Biomacromolecules 21:8, pages 3112-3121.
Crossref
Crossref
Tiago N. Figueira, Marco M. Domingues, Françoise Illien, Iris Cadima-Couto, Toni Todorovski, David Andreu, Sandrine Sagan, Miguel A. R. B. Castanho, Astrid Walrant & Ana Salomé Veiga. (2019) Enfuvirtide-Protoporphyrin IX Dual-Loaded Liposomes: In Vitro Evidence of Synergy against HIV-1 Entry into Cells. ACS Infectious Diseases 6:2, pages 224-236.
Crossref
Crossref
Gerard M. Jensen & Donald F. Hodgson. (2020) Opportunities and challenges in commercial pharmaceutical liposome applications. Advanced Drug Delivery Reviews 154-155, pages 2-12.
Crossref
Crossref
Kengo Banshoya, Yoshiharu Kaneo, Tetsuro Tanaka, Shigechika Yamamoto & Hiroshi Maeda. (2019) Synthesis and evaluation of styrene-maleic acid copolymer conjugated amphotericin B. International Journal of Pharmaceutics 572, pages 118719.
Crossref
Crossref
Wooseung Lee & Hyung-Jun Im. (2019) Theranostics Based on Liposome: Looking Back and Forward. Nuclear Medicine and Molecular Imaging 53:4, pages 242-246.
Crossref
Crossref
Jill Adler-Moore, Russell E Lewis, Roger J M Brüggemann, Bart J A Rijnders, Andreas H Groll & Thomas J Walsh. (2019) Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clinical Infectious Diseases 68:Supplement_4, pages S244-S259.
Crossref
Crossref
Eiichi Yamamoto. (2019) <i>In Vitro</i> Release Method for Liposome Drug Productsリポソーム製剤の研究開発における薬物放出評価法. YAKUGAKU ZASSHI 139:2, pages 249-254.
Crossref
Crossref
Jie Tang, Santhanakrishnan Srinivasan, Wenmin Yuan, Ran Ming, Yayuan Liu, Zhipeng Dai, Charles O. Noble, Mark E. Hayes, Nan Zheng, Wenlei Jiang, Francis C. Szoka & Anna Schwendeman. (2019) Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome. European Journal of Pharmaceutics and Biopharmaceutics 134, pages 107-116.
Crossref
Crossref
Jagadevappa S. Patil, Shivsharan B. Dhadde & Baburao N. Chandakavathe. 2019. Characterization and Biology of Nanomaterials for Drug Delivery. Characterization and Biology of Nanomaterials for Drug Delivery
165
197
.
Yuki Takechi-Haraya, Yukihiro Goda & Kumiko Sakai-Kato. (2018) Atomic Force Microscopy Study on the Stiffness of Nanosized Liposomes Containing Charged Lipids. Langmuir 34:26, pages 7805-7812.
Crossref
Crossref
Katrin Göke, Thomas Lorenz, Alexandros Repanas, Frederic Schneider, Denise Steiner, Knut Baumann, Heike Bunjes, Andreas Dietzel, Jan H. Finke, Birgit Glasmacher & Arno Kwade. (2018) Novel strategies for the formulation and processing of poorly water-soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics 126, pages 40-56.
Crossref
Crossref
Louise Walker, Prashant Sood, Megan D. Lenardon, Gillian Milne, Jon Olson, Gerard Jensen, Julie Wolf, Arturo Casadevall, Jill Adler-Moore & Neil A. R. Gow. (2018) The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles. mBio 9:1.
Crossref
Crossref
Stefano Colombo, Moritz Beck-Broichsitter, Johan Peter Bøtker, Martin Malmsten, Jukka Rantanen & Adam Bohr. (2018) Transforming nanomedicine manufacturing toward Quality by Design and microfluidics. Advanced Drug Delivery Reviews 128, pages 115-131.
Crossref
Crossref
Chirlie Silver & Sara Rostas. (2018) Comprehensive drug utilization review in neonates: liposomal amphotericin B. Journal of Pharmacy and Pharmacology 70:3, pages 328-334.
Crossref
Crossref
Romuald Bellmann & Piotr Smuszkiewicz. (2017) Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45:6, pages 737-779.
Crossref
Crossref
Aoke Wang, Aftab Ahmad, Sadeeq Ullah, Li Cheng, Lin Ke & Qipeng Yuan. (2017) A Cheap and Convenient Method of Liposome Preparation Using Glass Beads as a Source of Shear Force. AAPS PharmSciTech 18:8, pages 3227-3235.
Crossref
Crossref
Qamar Zia, Owais Mohammad, Mohd Ahmar Rauf, Wasi Khan & Swaleha Zubair. (2017) Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals. Scientific Reports 7:1.
Crossref
Crossref
M. Yamamoto, K. Iwanaga, T. Okinaga, W. Ariyoshi, K. Tominaga & T. Nishihara. (2017) Application of combination bubble liposomal amphotericin B and sonication has the dramatic effect on oral candidiasis. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 29:3, pages 193-197.
Crossref
Crossref
Upendra Bulbake, Sindhu Doppalapudi, Nagavendra Kommineni & Wahid Khan. (2017) Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9:4, pages 12.
Crossref
Crossref
Nita L. Seibel, Aziza T. Shad, Ihor Bekersky, Andreas H. Groll, Corina Gonzalez, Lauren V. Wood, Paul Jarosinski, Donald Buell, William W. Hope & Thomas J. Walsh. (2017) Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. Antimicrobial Agents and Chemotherapy 61:2.
Crossref
Crossref
Jean Cornier, Andrew Owen, Arno Kwade & Marcel Van de Voorde. 2017. Pharmaceutical Nanotechnology: Innovation and Production. Pharmaceutical Nanotechnology: Innovation and Production
175
230
.
Bhaskar Das & Sanjukta Patra. 2017. Nanostructures for Antimicrobial Therapy. Nanostructures for Antimicrobial Therapy
1
22
.
Jill P Adler-Moore, Jean-Pierre Gangneux & Peter G Pappas. (2016) Comparison between liposomal formulations of amphotericin B. Medical Mycology 54:3, pages 223-231.
Crossref
Crossref
Neil R. H. Stone, Tihana Bicanic, Rahuman Salim & William Hope. (2016) Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs 76:4, pages 485-500.
Crossref
Crossref
Chityal Ganesh Kumar, Sujitha Pombala, Yedla Poornachandra & Sankalp Vinod Agarwal. 2016. Nanobiomaterials in Antimicrobial Therapy. Nanobiomaterials in Antimicrobial Therapy
103
152
.
Takami Akagi & Mitsuru Akashi. 2016. Nanomaterials in Pharmacology. Nanomaterials in Pharmacology
439
455
.
Guanping Yu, Amita Vaidya, Da Sun & Zheng-Rong Lu. 2016. Nanomaterials in Pharmacology. Nanomaterials in Pharmacology
369
388
.
Hong Wen, Huijeong Jung & Xuhong Li. (2015) Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges. The AAPS Journal 17:6, pages 1327-1340.
Crossref
Crossref
F. FogliaS. E. RogersJ. R. P. WebsterF. A. Akeroyd, K. F. Gascoyne, M. J. LawrenceD. J. Barlow. (2015) Neutron Scattering Studies of the Effects of Formulating Amphotericin B with Cholesteryl Sulfate on the Drug’s Interactions with Phospholipid and Phospholipid–Sterol Membranes. Langmuir 31:29, pages 8042-8051.
Crossref
Crossref
. 2014. Safety of Nanomaterials along Their Lifecycle. Safety of Nanomaterials along Their Lifecycle
140
165
.
Chris Stockmann, Jonathan E. Constance, Jessica K. Roberts, Jared Olson, Elizabeth H. Doby, Krow Ampofo, Justin Stiers, Michael G. Spigarelli & Catherine M. T. Sherwin. (2014) Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications. Clinical Pharmacokinetics 53:5, pages 429-454.
Crossref
Crossref
Karolina Alicja Les, Abeer H. A. Mohamed-Ahmed, Sibu Balan, Ji-won Choi, Denis Martin, Vanessa Yardley, Keith Powell, Antony Godwin & Steve Brocchini. (2014) Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases. Polym. Chem. 5:3, pages 1037-1048.
Crossref
Crossref
Takayuki Takeda, Hideki Itano, Ryouhei Kakehashi, Shinichi Fukita, Masahiko Saitoh & Sorou Takeda. (2014) Direct transbronchial administration of liposomal amphotericin B into a pulmonary aspergilloma. Respiratory Medicine Case Reports 11, pages 7-11.
Crossref
Crossref
Nan Zheng, Wenlei Jiang, Robert Lionberger & Lawrence X. Yu. 2014. FDA Bioequivalence Standards. FDA Bioequivalence Standards
275
296
.
M. Anaul Kabir & Zulfiqar Ahmad. (2013)
Candida
Infections and Their Prevention
. ISRN Preventive Medicine 2013, pages 1-13.
Crossref
Crossref
T.T.H. Pham, P.M. Loiseau & G. Barratt. (2013) Strategies for the design of orally bioavailable antileishmanial treatments. International Journal of Pharmaceutics 454:1, pages 539-552.
Crossref
Crossref
Till Saxer, Andreas Zumbuehl & Bert Müller. (2013) The use of shear stress for targeted drug delivery. Cardiovascular Research 99:2, pages 328-333.
Crossref
Crossref
Richard J. Hamill. (2013) Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs 73:9, pages 919-934.
Crossref
Crossref
Abeer H. A. Mohamed-AhmedKarolina A. LesKarin SeifertSimon L. CroftStephen Brocchini. (2013) Noncovalent Complexation of Amphotericin-B with Poly(α-glutamic acid). Molecular Pharmaceutics 10:3, pages 940-950.
Crossref
Crossref
Hee Dong Han, Suk Hyun Jung, Hasoo Seong, Sun Hang Cho & Byung Cheol Shin. (2013) Dual Functional Gd(III)-DOTA Liposomes for Cancer Therapy and Diagnosis as a Theragnostic Carrier. Bulletin of the Korean Chemical Society 34:1, pages 154-158.
Crossref
Crossref
Pho Nguyen, Alex Huang & Samuel C. Yiu. (2013) Nanobiotechnology in the Management of Glaucoma. Open Journal of Ophthalmology 03:04, pages 127-133.
Crossref
Crossref
Abeer H. A. Mohamed-Ahmed, Karolina A. Les, Simon L. Croft & Stephen Brocchini. (2013) Preparation and characterisation of amphotericin B-copolymer complex for the treatment of leishmaniasis. Polym. Chem. 4:3, pages 584-591.
Crossref
Crossref
Christine Vauthier, Patrick Couvreur & Elias Fattal. 2013. Nanomaterials: A Danger or a Promise?. Nanomaterials: A Danger or a Promise?
131
151
.
Suk Hyun Jung, Kyunga Na, Seul A Lee, Sun Hang Cho, Hasoo Seong & Byung Cheol Shin. (2012) Gd(III)-DOTA-modified sonosensitive liposomes for ultrasound-triggered release and MR imaging. Nanoscale Research Letters 7:1.
Crossref
Crossref
Chau Chun Beh, Raffaella Mammucari & Neil R. Foster. (2012) Lipids-based drug carrier systems by dense gas technology: A review. Chemical Engineering Journal 188, pages 1-14.
Crossref
Crossref
P. M. Honoré, R. Jacobs & H. D. Spapen. 2012. Annual Update in Intensive Care and Emergency Medicine 2012. Annual Update in Intensive Care and Emergency Medicine 2012
337
344
.
Stefan Weiler, Helene Vogelsinger, Michael Joannidis, Stefan Dunzendorfer & Romuald Bellmann. (2011) Influence of Albumin Dialysis on Pharmacokinetics of Amphotericin B Colloidal Dispersion and Amphotericin B Lipid Complex. Artificial Organs 35:6, pages 667-671.
Crossref
Crossref
John Cannon. 2011. Drug Delivery Systems, Third Edition. Drug Delivery Systems, Third Edition
1
46
.
F. Tiberg & M. Johnsson. (2011) Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles. Journal of Drug Delivery Science and Technology 21:1, pages 101-109.
Crossref
Crossref
Christine Vauthier, Isabelle Bertholon & Denis Labarre. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
36
.
Miho Shinohara, Masahiro Nagao & Shiro Matsubara. (2010) Successful treatment of multiple sinus thromboses and meningitis due to aspergilli and .ALPHA.-streptococci with preemptive antimycotic therapy: a case report. Rinsho Shinkeigaku 50:9, pages 656-660.
Crossref
Crossref
P. Roussos, R. E. Lewis & D. P. Kontoyiannis. (2009) Azoles and antidepressants: a mini-review of the tolerability of co-administration. Mycoses 52:5, pages 433-439.
Crossref
Crossref
Suk Hyun Jung, Deok Hwi Lim, Soon Hwa Jung, Jung Eun Lee, Kyu-Sung Jeong, Hasoo Seong & Byung Cheol Shin. (2009) Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. European Journal of Pharmaceutical Sciences 37:3-4, pages 313-320.
Crossref
Crossref
Bijoy P. Mathew & Mahendra Nath. (2009) Recent Approaches to Antifungal Therapy for Invasive Mycoses. ChemMedChem 4:3, pages 310-323.
Crossref
Crossref
Paul O. Gubbins & Elias J. Anaissie. 2009. Clinical Mycology. Clinical Mycology
161
195
.
Megan Tufteland, Gang Ren & Robert O. Ryan. (2008) Nanodisks Derived from Amphotericin B Lipid Complex. Journal of Pharmaceutical Sciences 97:10, pages 4425-4432.
Crossref
Crossref
Michael Ellis. (2008) New dosing strategies for liposomal amphotericin B in high-risk patients. Clinical Microbiology and Infection 14, pages 55-64.
Crossref
Crossref
J.P. Adler-Moore & R.T. Proffitt. (2008) Amphotericin B lipid preparations: what are the differences?. Clinical Microbiology and Infection 14, pages 25-36.
Crossref
Crossref
Valérie Paquet, Astrid A. Volmer & Erick M. Carreira. (2008) Synthesis and In Vitro Biological Properties of Novel Cationic Derivatives of Amphotericin B. Chemistry – A European Journal 14:8, pages 2465-2481.
Crossref
Crossref
John Cannon, Sophia Paspal & Rong (Ron) Liu. 2008. Water-Insoluble Drug Formulation, Second Edition. Water-Insoluble Drug Formulation, Second Edition
375
415
.
Jon A. Olson, Jill P. Adler-Moore, Gerard M. Jensen, Julie Schwartz, M. Cecilia Dignani & Richard T. Proffitt. (2008) Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products. Antimicrobial Agents and Chemotherapy 52:1, pages 259-268.
Crossref
Crossref
Georg Maschmeyer, Antje Haas & Oliver A Cornely. (2007) Invasive Aspergillosis. Drugs 67:11, pages 1567-1601.
Crossref
Crossref
Takashi Maniwa & Yutaka Yamamoto. (2007) . Folia Pharmacologica Japonica 129:2, pages 129-134.
Crossref
Crossref
R. A. Barnes & J. Sinha. 2007. Infectious Diseases in Critical Care. Infectious Diseases in Critical Care
65
77
.
J. A. Paiva & J. M. Pereira. 2007. Infectious Diseases in Critical Care. Infectious Diseases in Critical Care
100
121
.
Malika Larabi, Philippe Legrand & Gillian Barratt. 2006. Liposome Technology, Volume II. Liposome Technology, Volume II
93
110
.
Patrick Couvreur & Christine Vauthier. (2006) Nanotechnology: Intelligent Design to Treat Complex Disease. Pharmaceutical Research 23:7, pages 1417-1450.
Crossref
Crossref
Koji Takemoto, Yutaka Yamamoto, Yutaka Ueda, Yoshihiro Sumita, Koichiro Yoshida & Yoshihito Niki. (2006) Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy 57:4, pages 724-731.
Crossref
Crossref
Helene Vogelsinger, Michael Joannidis, Jordan Kountchev, Rosa Bellmann-Weiler, Christian J. Wiedermann & Romuald Bellmann. (2006) Pharmacokinetics of Liposomal Amphotericin B During Extracorporeal Albumin Dialysis.. Artificial Organs 30:2, pages 118-121.
Crossref
Crossref
Yutaka Yamamoto. (2006) "Novel applications of DDS on infectious diseases and future prospect" Application of DDS to fungal infection diseases. Drug Delivery System 21:5, pages 529-535.
Crossref
Crossref
Kazuo Maruyama, Tomoko Takizawa, Ryo Suzuki & Naoki Utoguchi. (2006) "Novel applications of DDS on infectious diseases and future prospect" Development of PEG-immunoliposomes encapsulating amphotericin B. Drug Delivery System 21:5, pages 516-522.
Crossref
Crossref
Peter L. Hargreaves, Thanh-Son Nguyen & Robert O. Ryan. (2006) Spectroscopic studies of amphotericin B solubilized in nanoscale bilayer membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1758:1, pages 38-44.
Crossref
Crossref
Maciej Baginski, Barbara Cybulska & Wieslaw I. Gruszecki. 2006. Advances in Planar Lipid Bilayers and Liposomes Volume 3. Advances in Planar Lipid Bilayers and Liposomes Volume 3
269
329
.
Richard Proffitt & Jill Adler-Moore. 2005. Injectable Dispersed Systems. Injectable Dispersed Systems
481
525
.
Neil Soni & Adrian Wagstaff. (2005) Fungal infection. Current Anaesthesia & Critical Care 16:4, pages 231-241.
Crossref
Crossref
Leila Zarif. 2005. Liposomes. Liposomes
314
329
.
Roberta Gaziano, Silvia Bozza, Silvia Bellocchio, Katia Perruccio, Claudia Montagnoli, Lucia Pitzurra, Giovanni Salvatori, Rita De Santis, Paolo Carminati, Alberto Mantovani & Luigina Romani. (2004)
Anti-
Aspergillus fumigatus
Efficacy of Pentraxin 3 Alone and in Combination with Antifungals
. Antimicrobial Agents and Chemotherapy 48:11, pages 4414-4421.
Crossref
Crossref
Rama Falk, Jacob Grunwald, Amnon Hoffman, Abraham J. Domb & Itzhack Polacheck. (2004) Distribution of Amphotericin B-Arabinogalactan Conjugate in Mouse Tissue and Its Therapeutic Efficacy against Murine Aspergillosis. Antimicrobial Agents and Chemotherapy 48:9, pages 3606-3609.
Crossref
Crossref
Begoña Brime, Gloria Molero, Paloma Frutos & Gloria Frutos. (2004) Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil–water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans. European Journal of Pharmaceutical Sciences 22:5, pages 451-458.
Crossref
Crossref
Malika Larabi, Annette Gulik, Jean-Paul Dedieu, Philippe Legrand, Gillian Barratt & Monique Cheron. (2004) New lipid formulation of amphotericin B: spectral and microscopic analysis. Biochimica et Biophysica Acta (BBA) - Biomembranes 1664:2, pages 172-181.
Crossref
Crossref
Daniel A C Frattarelli, Michael D Reed, George P Giacoia & Jacob V Aranda. (2004) Antifungals in Systemic Neonatal Candidiasis. Drugs 64:9, pages 949-968.
Crossref
Crossref
J. P. Adler-Moore & R. T. Proffitt. 2004. Human Fungal Pathogens. Human Fungal Pathogens
339
362
.
Hiroshi Fukui, Tomohiro Koike, Takashi Nakagawa, Akira Saheki, Satoru Sonoke, Yoshifumi Tomii & Junzo Seki. (2003) Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®), with commercial lipid-based formulations. International Journal of Pharmaceutics 267:1-2, pages 101-112.
Crossref
Crossref
D.P. Kontoyiannis, E. Mantadakis & G. Samonis. (2003) Systemic mycoses in the immunocompromised host: an update in antifungal therapy. Journal of Hospital Infection 53:4, pages 243-258.
Crossref
Crossref
Johannes Müller, Annemarie Polak, Reinhard Kappe, Dagmar Rimek, Michael Seibold & Kathrin TintelnotAnnemarie Polak. 2003. Antifungal Agents. Antifungal Agents
59
190
.
Ignacio Segarra, Diane A. Movshin & Leila Zarif. (2002) Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid‐based delivery system. Journal of Pharmaceutical Sciences 91:8, pages 1827-1837.
Crossref
Crossref
A. Stuecklin‐Utsch, C. Hasan, U. Bode & G. Fleischhack. (2002) Pancreatic toxicity after liposomal amphotericin B
. Mycoses 45:5-6, pages 170-173.
Crossref
Crossref
Leila Zarif. (2002) Elongated supramolecular assemblies in drug delivery. Journal of Controlled Release 81:1-2, pages 7-23.
Crossref
Crossref
Begoña Brime, Marco A. Moreno, Gloria Frutos, Ma.Paloma Ballesteros & Paloma Frutos. (2002) Amphotericin B in Oil–Water Lecithin-Based Microemulsions: Formulation and Toxicity Evaluation. Journal of Pharmaceutical Sciences 91:4, pages 1178-1185.
Crossref
Crossref
Neil Soni. 2002. Fungal Infection in the Intensive Care Unit. Fungal Infection in the Intensive Care Unit
139
164
.
Thomas J. Walsh, Jesse L. GoodmanPeter PappasIhor Bekersky, Donald N. Buell, Maureen Roden, John BarrettElias J. Anaissie. (2001)
Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with
Aspergillus
Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
. Antimicrobial Agents and Chemotherapy 45:12, pages 3487-3496.
Crossref
Crossref
H Merhav, R Nakache, I Houri & R Orni-Wasserlauf. (2001) Liposomal amphotericin B (Ambisome) is safe and effective in the treatment of invasive mycosis in organ transplant patients. Transplantation Proceedings 33:6, pages 2937-2938.
Crossref
Crossref
Rosemary A. Barnes. 2001. Critical Care Infectious Diseases Textbook. Critical Care Infectious Diseases Textbook
57
75
.
José-Artur Paiva. 2001. Critical Care Infectious Diseases Textbook. Critical Care Infectious Diseases Textbook
195
223
.
J. R. Wingard, M. H. White, E. Anaissie, J. Raffalli, J. Goodman & A. Arrieta. (2000) A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia. Clinical Infectious Diseases 31:5, pages 1155-1163.
Crossref
Crossref
Adedayo AdedoyinChristine E. Swenson, Lois E. Bolcsak, Andrzej Hellmann, Danuta Radowska, Gary Horwith, Andrew S. Janoff & Robert A. Branch. (2000) A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients with Definite or Probable Systemic Fungal Infections. Antimicrobial Agents and Chemotherapy 44:10, pages 2900-2902.
Crossref
Crossref
Rosaria Santangelo, Padmaja Paderu, Guillaume Delmas, Zi-Wei Chen, Raphael Mannino, Leila Zarif & David S. Perlin. (2000) Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis. Antimicrobial Agents and Chemotherapy 44:9, pages 2356-2360.
Crossref
Crossref
April Garcia, Jill P. Adler-Moore & Richard T. Proffitt. (2000) Single-Dose AmBisome (Liposomal Amphotericin B) as Prophylaxis for Murine Systemic Candidiasis and Histoplasmosis. Antimicrobial Agents and Chemotherapy 44:9, pages 2327-2332.
Crossref
Crossref
Ayelet M Samuni, Alexander Lipman & Yechezkel Barenholz. (2000) Damage to liposomal lipids: protection by antioxidants and cholesterol-mediated dehydration. Chemistry and Physics of Lipids 105:2, pages 121-134.
Crossref
Crossref
N. Soni. 2000. Yearbook of Intensive Care and Emergency Medicine 2000. Yearbook of Intensive Care and Emergency Medicine 2000
144
159
.
Kunikazu Moribe, Kazuo Maruyama & Motoharu Iwatsuru. (1999) Molecular localization and state of amphotericin B in PEG liposomes. International Journal of Pharmaceutics 193:1, pages 97-106.
Crossref
Crossref
Ihor Bekersky, Robert M Fielding, Donald Buell & Ira Lawrence. (1999) Lipid-based amphotericin B formulations: from animals to man. Pharmaceutical Science & Technology Today 2:6, pages 230-236.
Crossref
Crossref
Thomas J. Walsh, Robert W. Finberg, Carola Arndt, John Hiemenz, Cindy Schwartz, David Bodensteiner, Peter Pappas, Nita Seibel, Richard N. Greenberg, Stephen Dummer, Mindy Schuster, William E. Dismukes & John S. Holcenberg. (1999) Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia. New England Journal of Medicine 340:10, pages 764-771.
Crossref
Crossref
Han Myint. (1999) AmBisome: an overview of current use. Hospital Medicine 60:2, pages 123-126.
Crossref
Crossref
T. Lorf, F. Braun, R. Rüchel, A. Müller, B. Sattler & B. Ringe. (2002)
Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome
®
) after liver transplantation
. Mycoses 42:1-2, pages 47-53.
Crossref
Crossref
Thomas J. Walsh, Vijay Yeldandi, Maureen McEvoy, Corina Gonzalez, Stephen Chanock, Alison Freifeld, Nita I. Seibel, Patricia O. Whitcomb, Paul Jarosinski, Garry Boswell, Ihor Bekersky, Ala Alak, Donald Buell, John BarretWyndham Wilson. (1998) Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients. Antimicrobial Agents and Chemotherapy 42:9, pages 2391-2398.
Crossref
Crossref
G. W. Boswell, D. Buell & I. Bekersky. (2013) AmBisome (Liposomal Amphotericin B): A Comparative Review. The Journal of Clinical Pharmacology 38:7, pages 583-592.
Crossref
Crossref
SPERRY, CUA, WETZEL & ADLER-MOORE. (1998) Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Medical Mycology 36:3, pages 135-141.
Crossref
Crossref
F Braun, R Rüchel, T Lorf, R Canelo, A Müller, B Sattler & B Ringe. (1998) Is Liposomal Amphotericin B (Ambisome) an Effective Prophylaxis of Mycotic Infections After Liver Transplantation?. Transplantation Proceedings 30:4, pages 1481-1483.
Crossref
Crossref
Garry W. Boswell, Ihor Bekersky, Donald Buell, Richard Hiles & Thomas J. Walsh. (1998) Toxicological Profile and Pharmacokinetics of a Unilamellar Liposomal Vesicle Formulation of Amphotericin B in Rats. Antimicrobial Agents and Chemotherapy 42:2, pages 263-268.
Crossref
Crossref
Andreas H. Groll, Stephen C. Piscitelli & Thomas J. Walsh. 1998.
343
500
.
PAUL G. SCHMIDT, JILL P. ADLER-MOORE, ERIC A. FORSSEN & RICHARD T. PROFFITT. 1998. Medical Applications of Liposomes. Medical Applications of Liposomes
703
731
.
IRMA A.J.M. BAKKER-WOUDENBERG & ELS W.M. VAN ETTEN. 1998. Medical Applications of Liposomes. Medical Applications of Liposomes
181
188
.
Claudio Ronco & Rinaldo BellomoFausto De Lalla & Mario Cruciani. 1998. Critical Care Nephrology. Critical Care Nephrology
479
494
.
Els W. M. van Etten & Irma A. J. M. Bakker. 1998. Long Circulating Liposomes: Old Drugs, New Therapeutics. Long Circulating Liposomes: Old Drugs, New Therapeutics
207
211
.
Jill P. Adler-Moore & Richard T. Proffitt. 1998. Long Circulating Liposomes: Old Drugs, New Therapeutics. Long Circulating Liposomes: Old Drugs, New Therapeutics
185
206
.
B. Zernikow, Gudrun Fleischhack, Carola Hasan & U. Bode. (2009) Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports. Mycoses 40:9-10, pages 359-361.
Crossref
Crossref
F Gaboriau, M Chéron, C Petit & J Bolard. (1997) Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrobial Agents and Chemotherapy 41:11, pages 2345-2351.
Crossref
Crossref
D.D Lasic. (1997) Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. Journal of Controlled Release 48:2-3, pages 203-222.
Crossref
Crossref
V HeinemannD BosseU JehnB KähnyK WachholzA DebusP ScholzH J KolbW Wilmanns. (1997) Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrobial Agents and Chemotherapy 41:6, pages 1275-1280.
Crossref
Crossref
Miguel D. Reboiras, Martin J. Miller & Malcolm N. Jones. (1997) Liposome adsorption to Candida albicans. Colloids and Surfaces B: Biointerfaces 9:1-2, pages 101-107.
Crossref
Crossref
François Gaboriau, Monique Chéron, Liliane Leroy & Jacques Bolard. (1997) Physico-chemical properties of the heat-induced ‘superaggregates’ of amphotericin B. Biophysical Chemistry 66:1, pages 1-12.
Crossref
Crossref
Anya M. Hillery. (1997) Supramolecular lipidic drug delivery systems: From laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Advanced Drug Delivery Reviews 24:2-3, pages 345-363.
Crossref
Crossref
Jayesh Mehta. (1997) Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?. Leukemia Research 21:3, pages 183-188.
Crossref
Crossref
Ayelet M. Samuni, Yechezkel Barenholz, Daan J.A. Crommelin & Nicolaas J. Zuidam. (1997) γ-Irradiation Damage to Liposomes Differing in Composition and Their Protection by Nitroxides. Free Radical Biology and Medicine 23:7, pages 972-979.
Crossref
Crossref
V. Strippoli, D. Basti, F. D. D'Auria, N. Simonetti & T. Bruzzese. (1997) In vivo andin vitro antifungal activity of the polyene derivative SPA-S-753 against encapsulated form ofCryptococcus neoformans. Infection 25:1, pages 27-31.
Crossref
Crossref
G. Storm & E. Etten. (1997) Biopharmaceutical aspects of lipid formulations of amphotericin B. European Journal of Clinical Microbiology & Infectious Diseases 16:1, pages 64-73.
Crossref
Crossref
Richard M. Eglen, Mont R. Juchau, Gillian Edwards, Arthur H. Weston, Helen Wise, M. D. Murray, D. Craig Brater, Olivier Valdenaire, Philippe Vernier & Annemarie PolakAnnemarie Polak. 1997. Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques. Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques
219
318
.
Scott Hartsel & Jacques Bolard. (1996) Amphotericin B: new life for an old drug. Trends in Pharmacological Sciences 17:12, pages 445-449.
Crossref
Crossref
J BrajtburgJ Bolard. (1996) Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews 9:4, pages 512-531.
Crossref
Crossref
David W. Warnock & Colin K. Campbell. (1996) Medical mycology. Mycological Research 100:10, pages 1153-1162.
Crossref
Crossref
N H GeorgopapadakouT J Walsh. (1996) Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrobial Agents and Chemotherapy 40:2, pages 279-291.
Crossref
Crossref
Brian D. Wolf & Scott C. Hartsel. (1995) Osmotic stress sensitizes sterol-free phospholipid bilayers to the action of Amphotericin B. Biochimica et Biophysica Acta (BBA) - Biomembranes 1238:2, pages 156-162.
Crossref
Crossref
T J WalshK GarrettE FeurersteinM GirtonM AllendeJ BacherA FrancesconiR SchaufeleP A Pizzo. (1995) Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrobial Agents and Chemotherapy 39:5, pages 1065-1069.
Crossref
Crossref
Thomas J. Walsh & Caron A. Lyman. 1995. Infectious Complications of Cancer. Infectious Complications of Cancer
113
148
.
R.J. Hay. (1994) Liposomal amphotericin B, AmBisome. Journal of Infection 28, pages 35-43.
Crossref
Crossref